Posted by Michael Wonder on 21 Nov 2020
ADC Therapeutics announces FDA accepts biologics license application and grants priority review for loncastuximab tesirine for treatment of relapsed or refractory diffuse large B-cell lymphoma
20 November 2020 - Prescription Drug User Fee Act target action date of 21 May 2021.
ADC Therapeutics today announced that the U.S. FDA has accepted its biologics license application for loncastuximab tesirine for the treatment of relapsed or refractory diffuse large B-cell lymphoma and granted priority review status.
